Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
Ad hoc announcement pursuant to Art. 53 LR
- Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)
- IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)
- Sandoz sales grew +2% (cc, 0% USD) and core operating income in line with prior year (0% cc, 0% USD)
- Full year net sales grew +4% (cc, +6% USD) driven by strong Innovative Medicines performance
- Innovative Medicines (IM …